| UHS |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$6.00 vs. cons $5.66 |
HIGH |
| UHS |
Report |
Adjusted EBITDA net of NCI (Q2'26) |
BEAT |
pred ~$725M vs. cons ~$680M |
HIGH |
| UHS |
Report |
Same-facility acute adjusted admissions (YoY) |
BEAT |
pred ~+3.5% vs. cons +2.8% |
MEDIUM |
| UHS |
Guide |
FY2026 Adjusted EPS guidance |
BETTER |
guide raised to ~$24.0 mid vs. cons ~$23.5 (FY2026) |
MEDIUM |
| UHS |
Guide |
FY2026 Adjusted EBITDA net of NCI guidance |
BETTER |
guide ~$2.75B mid vs. prior/cons ~$2.71B (FY2026) |
MEDIUM |
| UHS |
Guide |
Florida DPP / Medicaid supplemental payment benefit |
BETTER |
pred ~$50M+ in-period benefit vs. $0 in prior guidance (Q2/FY2026) |
MEDIUM |
| UHS |
Guide |
Behavioral Health operating income (Q2'26) |
UNKNOWN |
pred ~$390M vs. cons $392.9M (Q2'26) |
LOW |
| UHS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.0% |
— |
MEDIUM |
| UHS |
Return |
5-day cumulative residual |
+8.0% (FOLLOW-THROUGH) |
CMS approved the Florida DPP during Q2 (HCA booked ~$400M retro benefit), giving UHS an in-period supplemental catch-up not in guidance, and peers printed strong acute volumes with guidance raises (THC +17.5%, HCA raised). Against a stock de-rated ~a third from highs with defensive positioning, a beat + guidance raise should drive genuine upward FY revisions and multiple re-rating rather than a one-off pop. Modest fade risk exists because part of the beat is the retroactive DPP one-timer and H2 still carries ACA-exchange erosion and California staffing costs, so net follow-through is positive but restrained. |
MEDIUM |